Document is current
Any future updates will be listed below
-
Authors
van der Noord, Vera E. https://orcid.org/0000-0002-9894-3239
McLaughlin, Ronan P.
Karuntu, Jessica S.
He, Jichao
Timmermans, A. Mieke
Basnet, Sunita K. C.
Long, Yi
Diab, Sarah Al Haj
Tadesse, Solomon
Proost, Natalie
van Gerwen, Bastiaan
Siteur, Bjørn
van de Ven, Marieke
Pont, Chantal
Le Dévédec, Sylvia E.
Martens, John W. M.
Wang, Shudong
Zhang, Yinghui
van de Water, Bob
-
Funding
Funding for this research was provided by:
European Research Council (767854)
European Research Council (322737)
European Research Council (322737)
European Research Council (767854)
European Research Council (767854)
European Research Council (767854)
European Research Council (767854)
European Research Council (767854)
European Research Council (767854)
European Research Council (767854)
European Research Council (322737)
European Research Council (767854)
Dutch Cancer Society (2021-14546)
Dutch Cancer Society (2021-14546)
Dutch Cancer Society (2021-14546)
- License Information
-
More Information
Article History
Received: 2 May 2025
Accepted: 30 September 2025
First Online: 8 January 2026
Declarations
:
: The in vivo studies were performed at the Intervention Unit of the Mouse Clinic for Cancer and Aging (MCCA, Amsterdam, the Netherlands) and protocols were approved by the animal ethics committee of the Netherlands Cancer Institute (AVD 301002016407 and work protocol IDs 1.4.8239, 1.5.8240 and 1.1.8915). The TMAs used in this study were previously generated [ ]. Their generation was approved by the Medical Ethics Committee of the Erasmus Medical Center, The Netherlands (MEC 02.953), and was conducted in accordance with the Declaration of Helsinki and the Code of Conduct of the Federation of Medical Scientific Societies in The Netherlands. Informed consent was obtained from all patients.
: S.W., S.A.H.D., S.T. and Y.L. have patents related to the CDK9 and CDK4/6 inhibitors used in this study. The authors declare no further competing interests.
